Pay in 4 interest-free payments of $5.09 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
While average weight loss with Saxenda may be less dramatic than with Wegovy or tirzepatide-based therapies, many individuals achieve meaningful, steady progress when the medication is paired with structured follow-up and behavioral support
In the SURMOUNT-1 clinical trial, patients using tirzepatide achieved average weight loss ranging from approximately 15% to over 20% of body weight depending on dosage and treatment duration
As long as patients can maintain these good habits long-term, they can successfully discontinue the medication without gaining weight back
Body weight, metabolic rate, specific goals, and individual response all influence what dose works best for you
Glucose-dependent insulinotropic peptide in the high-normal range is associated with increased carotid intimamedia thickness
